Gamma-delta T cell receptor (gamma-delta TCR) (gamma-delta TCR)

The Gamma-delta T cell receptor (gamma-delta TCR) is a multi-subunit protein complex found on gamma-delta T cells, a specialized subset of lymphocytes that bridge innate and adaptive immunity (Silva-Santos et al., Nature Reviews Cancer, 2019). Unlike conventional alpha-beta T cells, gamma-delta T cells recognize antigens in a non-MHC-restricted manner, allowing them to identify tumor cells that have downregulated MHC class I molecules to evade immune detection. This recognition is often mediated by the gamma-delta TCR itself or through co-receptors like NKG2D, which bind to stress ligands such as MICA, MICB, and ULBPs that are upregulated on malignant or physiologically stressed cells (Groh et al., Nature, 1998). In the tumor microenvironment, these cells exert potent cytotoxicity through the release of perforin and granzymes and the production of pro-inflammatory cytokines like IFN-gamma (Kabelitz et al., Frontiers in Immunology, 2020). Therapeutic strategies, such as those pioneered by GammaDelta Therapeutics (now Takeda), leverage these cells for allogeneic cell therapy or through bispecific engagers like ICT01 and LAVA-051 to trigger targeted anti-tumor activity (Takeda Pharmaceutical Company, 2021). These approaches aim to harness the rapid, broad-spectrum activity of gamma-delta T cells while minimizing the risk of graft-versus-host disease (GvHD).

Other names

Gamma-delta T-cell receptorTCR gamma/deltaNKG2D-ligand axisStress-induced ligand recognition systemVgamma9Vdelta2 T-cell receptor

Activation of gamma-delta T cells to induce direct cytotoxicity against tumor cells via non-MHC-restricted recognition of stress ligands or phosphoantigens.